肝微粒體是體外研究一個化合物的代謝(酶抑制，清除率和代謝鑒定)以及藥物-藥物相互作用的主要工具。通常根據(jù)特定細(xì)胞色素酶的活性水平來選擇微粒體。
齊氏生物提供的肝細(xì)胞微粒體，每批產(chǎn)品都經(jīng)過嚴(yán)格的制備、檢測，確保批次間穩(wěn)定性，然后于凍存管包裝，10 mg/管；-80℃保存，干冰運(yùn)輸。
用途：ADME及藥代動力學(xué)檢測試驗(yàn)
種屬：人/大鼠/小鼠/兔/狗/豬/猴 /牛
規(guī)格：0.5ml 20mg/ml
運(yùn)輸：凍存管，干冰運(yùn)輸。
微粒體產(chǎn)品被SCI論文引用（部分）：
1.Metabolism of chicoric acid by rat liver microsomes and bioactivity comparisons of chicoric acid and its metabolites
Q Liu, Y Wang, CX Xiao, W Wu, X Liu - Food & function, 2015 - pubs.rsc.org
… 11–14 Moreover, chicoric acid has showed anti-inflammatory, anti-bacterial, anti-HIV
activities, hypoglycemic and hepatocyte protective properties … Rat liver microsomes
were obtained from CHI Scientific, Inc. (Massachusetts, USA)
2.Hypoxia-triggered gene therapy: a new drug delivery system to utilize photodynamic-induced hypoxia for synergistic cancer therapy
C Huang, J Zheng, D Ma, N Liu, C Zhu, J Li… - Journal of Materials …, 2018 - pubs.rsc.org
… Rat liver microsomes were purchased from CHI Scientific (Jiangsu China … under hypoxic conditions
(red curve); DDS in the presence of inactive rat liver microsomes and NADPH … 0 represent the
fluorescence intensity of TAMRA after and before rat liver microsome addition under …
關(guān)鍵字： 肝微粒體;小鼠肝微粒體;肝細(xì)胞微粒體;
齊氏生物科技有限公司成立于2009年，是一家專注于原代細(xì)胞培養(yǎng)和篩選、體外藥物代謝和藥物間相互作用評價產(chǎn)品的公司，為全球藥物公司、藥物研究所、疾控中心、新藥安評中心和各類科研機(jī)構(gòu)提供符合標(biāo)準(zhǔn)規(guī)范產(chǎn)品，致力于打造原代細(xì)胞生物制藥研發(fā)和篩選平臺。